MCRB

MCRB is a clinical-stage live-biotherapeutics company whose headline 'profit' is an accounting mirage. FY2025 revenue was just $789K while operating income was -$94.0M (an operating margin of -11,910%); the $5.70M net income and the resulting 12.2x P/E exist only because of one-time items tied to the September 2024 sale of VOWST to Nestlé Health Science, not from a viable business. The 721.9% net margin and 12.9% ROE are artifacts of that distortion — backing them out, this is a company with essentially no product revenue and a -$972M accumulated deficit. The 94.5% drop in share count (9.59M shares) signals a large reverse split, another hallmark of a distressed equity.

The filing is unambiguous about the core problem: management states there is 'substantial doubt about our ability to continue as a going concern' and that, based on current cash, it will 'require additional funding following the third quarter of 2026.' With only $45.8M of cash against a ~$94M operating loss, the runway is short and the company concedes that raising capital or securing a partnership 'cannot be considered probable.' It explicitly names 'seeking relief under the U.S. Bankruptcy Code or winding down our operations' as alternatives — the worst-case is on the table, not hypothetical.